126 related articles for article (PubMed ID: 12879461)
1. Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders.
Younes A; Aggarwall BB
Cancer; 2003 Aug; 98(3):458-67. PubMed ID: 12879461
[TBL] [Abstract][Full Text] [Related]
2. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy.
Younes A; Kadin ME
J Clin Oncol; 2003 Sep; 21(18):3526-34. PubMed ID: 12972530
[TBL] [Abstract][Full Text] [Related]
3. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L.
Di Pietro R; Zauli G
J Cell Physiol; 2004 Dec; 201(3):331-40. PubMed ID: 15389537
[TBL] [Abstract][Full Text] [Related]
4. The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology.
Zauli G; Secchiero P
Cytokine Growth Factor Rev; 2006 Aug; 17(4):245-57. PubMed ID: 16750931
[TBL] [Abstract][Full Text] [Related]
5. TRAIL and apoptosis induction by TNF-family death receptors.
Wang S; El-Deiry WS
Oncogene; 2003 Nov; 22(53):8628-33. PubMed ID: 14634624
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of RANK ligand involved in bone metabolism.
Ito S; Hata T
Vitam Horm; 2004; 67():19-33. PubMed ID: 15110169
[TBL] [Abstract][Full Text] [Related]
8. Expression of tumor necrosis factor alpha, TNF-related apoptosis-inducing ligand, and their associated molecules in ameloblastomas.
Kumamoto H; Ooya K
J Oral Pathol Med; 2005 May; 34(5):287-94. PubMed ID: 15817072
[TBL] [Abstract][Full Text] [Related]
9. 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway.
Wang X; Ju W; Renouard J; Aden J; Belinsky SA; Lin Y
Cancer Res; 2006 Jan; 66(2):1089-95. PubMed ID: 16424045
[TBL] [Abstract][Full Text] [Related]
10. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors.
Aggarwal BB; Bhardwaj U; Takada Y
Vitam Horm; 2004; 67():453-83. PubMed ID: 15110190
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes.
Shin JY; Shin YG; Chung CH
Diabetes Care; 2006 Jul; 29(7):1664-6. PubMed ID: 16801598
[No Abstract] [Full Text] [Related]
12. The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease.
Brunetti G; Colucci S; Rizzi R; Mori G; Colaianni G; Oranger A; Zallone A; Liso V; Grano M
Ann N Y Acad Sci; 2006 Apr; 1068():334-40. PubMed ID: 16831934
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor and trail interactions in epithelial-derived cells.
Gibson SB
Vitam Horm; 2004; 67():207-27. PubMed ID: 15110179
[TBL] [Abstract][Full Text] [Related]
14. Osteoprotegerin is expressed in colon carcinoma cells.
Pettersen I; Bakkelund W; Smedsrød B; Sveinbjørnsson B
Anticancer Res; 2005; 25(6B):3809-16. PubMed ID: 16309167
[TBL] [Abstract][Full Text] [Related]
15. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?
Holen I; Cross SS; Neville-Webbe HL; Cross NA; Balasubramanian SP; Croucher PI; Evans CA; Lippitt JM; Coleman RE; Eaton CL
Breast Cancer Res Treat; 2005 Aug; 92(3):207-15. PubMed ID: 16155791
[TBL] [Abstract][Full Text] [Related]
16. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
Collin-Osdoby P
Circ Res; 2004 Nov; 95(11):1046-57. PubMed ID: 15564564
[TBL] [Abstract][Full Text] [Related]
17. On the production of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2L) by human neutrophils.
Cassatella MA
J Leukoc Biol; 2006 Jun; 79(6):1140-9. PubMed ID: 16574768
[TBL] [Abstract][Full Text] [Related]
18. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
[TBL] [Abstract][Full Text] [Related]
19. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy.
Sayers TJ; Murphy WJ
Cancer Immunol Immunother; 2006 Jan; 55(1):76-84. PubMed ID: 15864587
[TBL] [Abstract][Full Text] [Related]
20. Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules.
Tamada K; Chen L
Cancer Immunol Immunother; 2006 Apr; 55(4):355-62. PubMed ID: 16187084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
